Abstract
Improved understanding of prostate cancer biology in recent years has led to the development of new targeted agents for the treatment of castration-resistant prostate cancer, many of which are particularly effective on osseous disease, which is predominant in prostate cancer. We reviewed here some of these promising agents. Data from early Phase I/II trials are promising. In Phase III studies, the RANK ligand inhibitor denosumab was associated with a delay in the occurrence of bone metastasis, and a reduction in the incidence of skeletal-related events. With endothelin receptor antagonists, Phase III results have been disappointing. The results of a Phase III trial with the a-radiation emitter alpharadin are expected soon. The SRC tyrosine kinase inhibitors are also being tested in randomized trials.
Original language | English (US) |
---|---|
Title of host publication | Advances in Bone Metastasis Management |
Publisher | Future Medicine Ltd. |
Pages | 31-42 |
Number of pages | 12 |
ISBN (Electronic) | 9781780840307 |
ISBN (Print) | 9781780841151 |
DOIs | |
State | Published - Mar 1 2012 |
ASJC Scopus subject areas
- Medicine(all)